Beta Amyloid 1-42
Beta Amyloid 1-42 - Related Videos
06:34
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
0 Views •
Cited by 6 •
2017
Herein we report a tailored HPLC purification protocol that yields high-purity amyloid beta 42 (Aβ42) and amyloid beta 40 (Aβ40) peptides, capable of oligomer formation. Amyloid beta is a highly aggregation prone, hydrophobic peptide implicated in Alzheimer's disease. The amyloidogenic nature of the peptide makes its purification a challenge.
04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
0 Views •
Cited by 74 •
2010
One feature of Alzheimer's Disease is the elevation of Aβ1-42 peptide. Here we provide a protocol for preparing synthetic Aβ1-42 oligomers, which impairs hippocampal Long-Term Potentiation, a cellular correlate of memory. This procedure is useful for investigating mechanisms of Aβ-induced pathology and drug screening.
08:40
Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure
0 Views •
Cited by 5 •
2017
A reference measurement procedure for the absolute quantification of Aβ1-42 in human CSF based on solid-phase extraction and liquid chromatography tandem mass spectrometry is described.
08:16
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
0 Views •
Cited by 41 •
2015
Here, we present a protocol for direct stereotaxic brain infusion of amyloid-beta. This methodology provides an alternative in vivo mouse model to address the short-term effects of amyloid-beta on brain neurons.
01:25
Beta
0 Views •
2024
Beta is a crucial metric in finance used to assess an investment's risk and expected return relative to the overall market. It is calculated as the slope of the line in a scatterplot that compares the returns of an individual stock to the returns of the market benchmark, typically represented by a broad market index. Beta quantifies how much a stock's price moves in response to market movements, providing insight into its volatility and systematic risk. A beta of one indicates that the stock's...
FAQs
Aβ42 is relatively prone to misfolding, so it can progress through several molecular states rather than remaining as an isolated peptide. Soluble oligomers appear during this progression, followed by fibrillar deposits called amyloid plaques. Studying these transitions helps researchers connect peptide behavior with synaptic disruption, neuronal stress, and broader neurodegenerative processes associated with Alzheimer’s disease.
Soluble oligomers and fibrillar deposits represent different assembly states of Aβ42. Oligomers remain soluble, whereas fibrillar assemblies accumulate into amyloid plaques. This distinction allows researchers to examine whether changes in neuronal signaling and stress are associated with intermediate soluble assemblies, later deposits, or the progression between them. The comparison is therefore important for interpreting disease mechanisms.
β-secretase and γ-secretase act sequentially on amyloid precursor protein to generate Aβ42. Their cleavage activity places these enzymes upstream of the peptide’s later misfolding and assembly behavior. Consequently, research can examine Aβ42 production together with its downstream oligomerization and plaque formation, linking precursor processing to molecular events relevant to Alzheimer’s disease neuroscience.
Researchers measure Beta Amyloid 1-42 in cerebrospinal fluid, blood, and brain tissue. Using multiple specimen types allows investigations to examine the peptide in fluid compartments as well as directly in neural tissue. These measurements support studies of disease mechanisms and provide material for evaluating whether Aβ42 levels or distributions can contribute to biomarker and diagnostic research.
Aβ42 measurements can help researchers investigate how amyloid-related changes are associated with Alzheimer’s disease and neurodegenerative processes. They also support biomarker development and the evaluation of diagnostic approaches. By examining the peptide in cerebrospinal fluid, blood, or brain tissue, studies can compare molecular findings across biological contexts without relying on a single type of evidence.
Potential therapies can be assessed by examining their effects on Aβ42-related biology. Researchers may use measurements of the peptide to study disease mechanisms, evaluate changes relevant to amyloid processing or assembly, and determine whether an intervention produces a measurable molecular outcome. This makes Aβ42 useful for connecting experimental treatment studies with Alzheimer’s disease research objectives.